Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie dotyczące kontynuacji leczenia guselkumabem u pacjentów z łuszczycowym zapaleniem stawów (PEGASUS)

2 listopada 2026 zaktualizowane przez: Janssen-Cilag Ltd.

Real-World, prospektywne badanie trwałości leczenia guselkumabem u pacjentów z łuszczycowym zapaleniem stawów

This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).

Przegląd badań

Status

Rekrutacyjny

Warunki

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

200

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

      • Lille, Francja, 59037
        • Rekrutacyjny
        • Hopital Roger Salengro - CHU Lille

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

The study population will include participants affected with psoriatic arthritis (PsA) according to classification for psoriatic arthritis (CASPAR) criteria.

Opis

Inclusion criteria:

  • Have a confirmed diagnosis of psoriatic arthritis (PsA) as determined by a rheumatologist with reference to ClASsification criteria for Psoriatic ARthritis (CASPAR)
  • Start guselkumab as a first, second, third, or fourth line of disease-modifying antirheumatic drug (bDMARD) therapy for the indication of PsA as part of standard clinical practice at the time of enrollment into the observational study
  • Initiating guselkumab treatment according to Summary of Product Characteristics (SmPC) indication
  • The treatment decision must be taken by the participating rheumatologist prior to, and independently of the patient's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations
  • Must have received the information note, given his/her oral agreement and has not objected to the collection of his/her data in accordance with French requirements

Exclusion Criteria:

  • Have already taken a specific interleukin-23 inhibitor (IL-23i) treatment.
  • Are receiving combination therapy: 2 or more targeted therapies (biotherapy, Janus kinase [JAK] inhibitor, phosphodiesterase 4 (PDE4) inhibitor) indicated for PsA/PsO at the same time
  • Has a contra-indication to guselkumab according to the SmPC (for hypersensitivity or due to active clinically important infection, example active tuberculosis)
  • Unwilling or unable to participate in long-term data collection
  • Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study ( that is, signing of informed consent)
  • Currently enrolled in any interventional study or any Janssen-Cilag France-sponsored observational clinical study
  • Is under guardianship or curatorship, judicial protection, future protection mandate or under family authorization

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: COHORT
  • Perspektywy czasowe: PROSPECTIVE

Kohorty i interwencje

Grupa / Kohorta
Group 1: Psoriatic Arthritis Participants Treated With Guselkumab

Participants with confirmed diagnosis of psoriatic arthritis treated with guselkumab as per routine clinical practice will be enrolled. No drug will be provided as part of this study. Only data available within routine clinical practice will be collected in this study.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Proportion of Participants Still Receiving Treatment at 1 Year
Ramy czasowe: At 1 year

Discontinuation or maintenance of guselkumab treatment will be recorded by the physician at each visit. Proportion of participants still receiving treatment will be reported in the outcome measure.

At 1 year
Percentage of Participants Still Receiving Treatment at Persistence Time
Ramy czasowe: Up to 8 weeks

Persistence time of the initial treatment: defined as the time from the date of the first administration of guselkumab to the date that the last dose of guselkumab treatment was administered plus 1 dosing interval (8 weeks), or until start of subsequent treatment.

Up to 8 weeks
Number of Participants Starting New Treatment
Ramy czasowe: At 1 year

Participants starting new treatment along with reason of discontinuation will be reported.

At 1 year

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants Still Receiving Treatment at 2 years
Ramy czasowe: At 2 years

Percentage of participants still receiving treatment at 2 years will be reported.

At 2 years
Percentage of Participants Discontinuing The Treatment
Ramy czasowe: At 2 years

Participants discontinuing the treatment along with the reasons will be reported.

At 2 years
Change From Baseline in Disease Activity Index in Psoriatic Arthritis (DAPSA)/ Clinical Disease Activity Index in Psoriatic Arthritis (cDAPSA)
Ramy czasowe: Baseline, Months 3,6,12,18, and 24

The DAPSA was developed to characterize psoriatic arthritis (PsA) disease activity. It considers the number of painful and swollen joints, the patient's assessment of their disease and the C-reactive protein (CRP) measurement for acute inflammation. Where CRP measurements are not available, the clinical DAPSA (cDAPSA) maybe be used, which omits CRP. An overall score is calculated, where higher scores correspond to higher disease activity. Cut-off values for DAPSA low and high disease activity are: ≤14 and >28 points, respectively, and for remission is ≤4 points. The cut-off values for cDAPSA are: ≤4 points for remission, >4 to ≤13 points for low disease activity, > 13 to ≤27 points for moderate disease activity, and >27 points for high disease activity.

Baseline, Months 3,6,12,18, and 24
Change From Baseline in Leeds Enthesitis Index (LEI) Score
Ramy czasowe: Baseline, Months 3,6,12,18, and 24

The Leeds enthesitis index (LEI) measures the activity of enthesitis in PsA. The index measures the severity and activity of enthesitis, inflammation at the attachment of the ligaments and tendons to bone. The clinical assessor must elicit tenderness at 6 enthesitis sites: both lateral epicondyles of the humerus, both medial condyles of the femur, and the Achilles tendon insertions. Each site affected is summed to give a score out of 6, where 6 indicates all sites affected.

Baseline, Months 3,6,12,18, and 24
Change From Baseline in Back and Neck Pain Numerical Rating Scale (NRS) Score
Ramy czasowe: Baseline, Months 3,6,12,18, and 24

NRS for back and neck pain will be administered. This is a simple numbered 0-10 scale on which the patient indicates the intensity of their pain (0 represents no pain and 10 indicates the worst possible pain).

Baseline, Months 3,6,12,18, and 24
Hazard Ratios Between Baseline Clinical Factors and Guselkumab Persistence and Effectiveness at Months 12 and 24
Ramy czasowe: At Month 12 and 24

Hazard ratios for association between baseline clinical factors and persistence/effectiveness from Cox proportional hazards models will be reported.

At Month 12 and 24
Sociodemographic Characteristics: Age
Ramy czasowe: At Baseline

Participant's age will be reported.

At Baseline
Sociodemographic Characteristics: Sex
Ramy czasowe: At Baseline

Participant's sex (male, female) will be reported

At Baseline
Sociodemographic Characteristics: Weight
Ramy czasowe: At Baseline

Participant's weight will be reported

At Baseline
Sociodemographic Characteristics: Height
Ramy czasowe: At Baseline

Participant's height will be reported.

At Baseline
Sociodemographic Characteristics: Body Mass Index (BMI)
Ramy czasowe: At Baseline

Participant's BMI will be reported.

At Baseline
Number of Participants Reporting Smoking, Cannabis and Alcohol Use
Ramy czasowe: At Baseline

Participant's smoking, use of Cannabis and Alcohol habit will be reported.

At Baseline
Number of Participants With Family History of Psoriasis and/or Psoriatic Arthritis and/or Spondyloarthritis
Ramy czasowe: At Baseline

Family history of psoriasis and/or psoriatic arthritis and/or spondyloarthritis wil be reported.

At Baseline
Date of Diagnosis of Psoriatic Arthritis
Ramy czasowe: At Baseline

Date of diagnosis of psoriatic arthritis will be reported.

At Baseline
Date of Previous Treatments of Psoriatic Arthritis
Ramy czasowe: At Baseline

Date of previous treatments of psoriatic arthritis will be reported.

At Baseline
Duration of Previous Treatments of Psoriatic Arthritis
Ramy czasowe: At Baseline

Duration of previous treatments of psoriatic arthritis will be reported.

At Baseline
Medical History and Current Situation
Ramy czasowe: At Baseline

Participants medical history and current medical situation will be reported.

At Baseline
Number of Participants Receiving Co-occurring Treatments Linked to Psoriatic Arthritis
Ramy czasowe: Baseline up to 2 Years

Participants receiving co-occurring treatments linked to psoriatic arthritis at baseline and during follow-up will be reported.

Baseline up to 2 Years
Failure to Achieve or Maintain Response
Ramy czasowe: Up to 2 Years

Failure to achieve or maintain response to at least 2 biologic/targeted synthetic DMARDs with at least 2 different mechanisms of action (Y/N) (For treatment refractory criteria).

Up to 2 Years
Number of Participants Reporting Problems Related to the Management of Signs and Symptoms
Ramy czasowe: At baseline

The management of signs and/or symptoms that is perceived as problematic by the rheumatologist and/or the participants will be reported.

At baseline
Evidence of Persistent Disease
Ramy czasowe: Up to 2 Years

Evidence of persistent disease as defined by at least 2 of the following: a) failure to achieve or maintain low disease activity, b) the presence of active extra-musculoskeletal manifestations of PsA, c) objective evidence of inflammatory activity, namely clinical signs, elevated acute phase reactants and/or imaging findings suggestive of inflammation.

Up to 2 Years
Number of Participants with Co-Morbidities
Ramy czasowe: At baseline

Number of participants with co-morbidities will be reported.

At baseline
Number of Participants with Abnormal Psychosocial Factors
Ramy czasowe: At Baseline

Number of participants with abnormal psychosocial factors will be reported.

At Baseline
Healthcare Professional (HCP): Age Group
Ramy czasowe: At Baseline

Age group of HCP will be reported.

At Baseline
HCP: Sex
Ramy czasowe: At Baseline

Sex of HCP will be reported.

At Baseline
HCP: Experience
Ramy czasowe: At Baseline

Experience of HCP will be reported.

At Baseline
HCP: Type of Practice
Ramy czasowe: At Baseline

Type of practice of HCP will be reported.

At Baseline
Number of Participants With Adverse Events, Serious Adverse Events, Infections and Injection Site Reactions
Ramy czasowe: Up to 2 Years

AEs with onset or worsening on or after date of first dose of study treatment. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1 equal (=) Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to AE. SAE is any untoward medical occurrence that results in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

Up to 2 Years
Tolerance Related Guselkumab Treatment
Ramy czasowe: Up to 2 Years

Tolerance Related guselkumab treatment will be reported.

Up to 2 Years
Dose at Initiation of Guselkumab
Ramy czasowe: At Months 0, 3, 6, 12, 18 and 24

Dose at initiation of guselkumab will be reported.

At Months 0, 3, 6, 12, 18 and 24
Treatment Interval at Initiation of Guselkumab
Ramy czasowe: At Months 0, 3, 6, 12, 18 and 24

Treatment interval at initiation of guselkumab will be reported.

At Months 0, 3, 6, 12, 18 and 24
Type of Injection
Ramy czasowe: At Months 0, 3, 6, 12, 18 and 24

Type of injection will be reported.

At Months 0, 3, 6, 12, 18 and 24
Number of Participants Reporting Change of Injection Frequency
Ramy czasowe: At Months 0, 3, 6, 12, 18 and 24

Participants reporting change of injection frequency (Q4 to Q8 or Q8 to Q4) and its reason will be reported.

At Months 0, 3, 6, 12, 18 and 24
Number of Participant With Co-occurring Treatments Linked to PSA
Ramy czasowe: At Months 0, 3, 6, 12, 18 and 24

Participants with co-occurring treatments linked to PSA will be reported.

At Months 0, 3, 6, 12, 18 and 24
Number of Participants With Reason for Choosing Guselkumab From the Therapeutic Arsenal
Ramy czasowe: At Months 0, 3, 6, 12, 18 and 24

Participants with reason for choosing guselkumab from the therapeutic arsenal will be reported.

At Months 0, 3, 6, 12, 18 and 24
Number of Participants Switching to New Treatment in Case of Discontinuation of Guselkumab Treatment
Ramy czasowe: At Months 0, 3, 6, 12, 18 and 24

Participants switching to new treatment in case of discontinuation of guselkumab treatment will be reported.

At Months 0, 3, 6, 12, 18 and 24
Change From Baseline in 12-item Psoriatic Arthritis Impact of Disease Questionnaire (PsAID-12) Questionnaire Score
Ramy czasowe: Baseline, Months 0, 3, 6, 12, 18 and 24

The PsAID-12 questionnaire was designed to assess the impact of disease, with questions on pain, physical function, fatigue, coping and depression. It is a validated, self-administered questionnaire developed for use in clinical practice that assesses the impact of PsA on patients' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly).

Baseline, Months 0, 3, 6, 12, 18 and 24
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Each Visit After Baseline
Ramy czasowe: Baseline, Months 0, 3, 6, 12, 18 and 24

The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) was developed to measure disease activity in patients with ankylosing spondylitis. It consists of 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration and morning stiffness severity. Each symptom is assessed on a scale of 0-10 where 0 indicates no pain or discomfort and 10 indicates maximum pain or discomfort. To give each symptom equal weighting, the mean (average) of the 2 scores relating to morning stiffness is taken. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score. Scores of 4 or greater suggest suboptimal control of disease.

Baseline, Months 0, 3, 6, 12, 18 and 24
Satisfaction of Treatment for the Participants
Ramy czasowe: At Months 3, 6, 12, 18 and 24

The satisfaction of treatment for the participant will be assessed using a 5-point Likert scale, ("Very dissatisfied Dissatisfied Neither satisfied nor dissatisfied Satisfied Very satisfied"). The scale includes two patient reported questions: "1) How satisfied or dissatisfied are you with the overall convenience of this medication" and "2) How satisfied or dissatisfied are you with the ability of this medication ability to treat your condition?" Scores range from Very dissatisfied to Very satisfied and will be used to evaluate satisfaction with guselkumab treatment.

At Months 3, 6, 12, 18 and 24
Satisfaction of Treatment Care Management and Patient Relationship for the Rheumatologist
Ramy czasowe: At Months 3, 6, 12, 18 and 24

Satisfaction of treatment care management and patient relationship for the rheumatologist will be assessed using a 5-point Likert scale specified as : "Very dissatisfied, Dissatisfied, Neither satisfied nor dissatisfied, Satisfied and Very satisfied." The physician-reported questions are: "1) How satisfied or dissatisfied are you with this drug overall for this patient?" and "2) How satisfied or dissatisfied are you with the ease of managing your patient with guselkumab?"

At Months 3, 6, 12, 18 and 24

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Dyrektor Studium: Janssen-Cilag France Clinical Trial, Janssen-Cilag France

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

17 kwietnia 2026

Zakończenie podstawowe (Szacowany)

10 grudnia 2029

Ukończenie studiów (Szacowany)

10 grudnia 2029

Daty rejestracji na studia

Pierwszy przesłany

8 kwietnia 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

8 kwietnia 2026

Pierwszy wysłany (Rzeczywisty)

15 kwietnia 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

3 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • CNTO1959PSA4021
  • CNTO1959PSA4021 (Inny identyfikator: Janssen Research & Development, LLC)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .